ChitogenX Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CHNXF research report →
Price Chart
About the company
ChitogenX Inc. is a biologics firm focused on orthopedic and sports medicine, committing its efforts to pioneering novel soft tissue repair technologies. The company's primary objective is to elevate the efficacy of sports medicine surgical procedures through its research and development.
- CEO
- Pierre Laurin
- IPO
- 2020
- Employees
- 5
- HQ
- Kirkland, QC, CA
Get TickerSpark's AI analysis on CHNXF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $627.63K
- P/E
- -0.23
- Fwd P/E
- 0.02
- PEG
- -0.00
- P/S
- 0.00
- P/B
- -0.06
- EV/EBITDA
- -6.35
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 19.40%
- ROIC
- 127.91%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-42,000+28.8%
- Op Income
- $-2,830,000
- Net Income
- $-1,554,000+75.1%
- EPS
- $-0.02+83.6%
- OCF Growth
- +68.4%
- FCF Growth
- +68.4%
- 52W High
- $0.01
- 52W Low
- $0.00
- 50D MA
- $0.01
- 200D MA
- $0.01
- Beta
- -2.09
- RSI (14)
- 96
- Avg Volume
- 39.44K
No earnings-call transcripts are available for CHNXF yet.
- Free Float
- 71.2%
- Shares Outstanding
- 83.13M
- Float Shares
- 59.23M
Our CHNXF coverage
Recent articles, reports, and earnings notes.
No research on CHNXF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CHNXF report →ChitogenX ends 3Q with improved financial outlook; key milestones achieved
proactiveinvestors.com · Jan 3
ChitogenX demonstrates ORTHO-R efficacy and osteoarthritis protection in large animal meniscal repair study
proactiveinvestors.com · Nov 9
ChitogenX targets multi-billion dollar burn and skin repair market
proactiveinvestors.com · Nov 7
CHITOGENX LAUNCHES BURN AND SKIN REPAIR DEVELOPMENT PROGRAM
prnewswire.com · Nov 7
ChitogenX ends 2Q with stronger balance sheet as it advances its flagship ORTHO-R platform
proactiveinvestors.com · Sep 29
ChitogenX receives notice of allowance for key patent in the US and Canada
proactiveinvestors.com · Sep 28
ChitogenX concludes enrolment for its US Phase I/II rotator cuff tear repair clinical trial
proactiveinvestors.com · Sep 26
ChitogenX reports first quarter results, highlights milestone in rotator cuff repair Phase I/II trial
proactiveinvestors.com · Jun 30
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.